All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Reported results | 2005-000941-12 | Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV me... | 2009-01-08 | due-trials |
| Reported results | 2009-016839-35 | A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma | 2017-12-05 | due-trials |
| Reported results | 2009-016840-38 | A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma | 2015-09-04 | due-trials |
| Reported results | 2012-000128-16 | A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone Versus Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma | 2018-02-05 | due-trials |
| Reported results | 2012-005283-97 | A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone versus Bortezomib, Melphalan, and Prednisone in Transplant ineligible Patients with Newly Diagnosed Multiple Myeloma | 2016-11-04 | due-trials |
| Exempt, with results | 2013-001169-18 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma | 2019-06-25 | not-yet-due |
| Exempt, with results | 2013-002125-27 | Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma | 2015-08-31 | not-yet-due |
| Exempt, with results | 2013-002597-44 | Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects with Previously Untreated Extensive-stage Small-cell Lung Cancer | 2017-05-04 | not-yet-due |
| Listed as ongoing, but also has a completion date | 2014-001633-84 | Phase 1b/2 Study of Carfilzomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblasti... | 2024-06-28 | bad-data |
| Reported results | 2014-005325-12 | A Randomized, Open-label, Phase 3 Study in Subjects with Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination with Dexamethasone, Comparing Once-weekly versus Twice-weekly Car... | 2019-01-07 | due-trials |